Clinical Trials Logo
  1. Home
  2. Guillain-Barre Syndrome
  3. NCT06032741
  4. Details
NCT06032741 Clinical Trial

Prognosis in Patients With Guillain-Barre Syndrome

Guillain-Barre Syndrome Clinical Trial

Official title:
Prognosis in Patients With Guillain-Barre Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06032741
Other study ID # GBS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 2, 2013
Est. completion date January 31, 2025

Study information
Verified date December 2022
Source First Affiliated Hospital of Wenzhou Medical University
Contact Binbin Deng
Phone dbinbin@aliyun.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

Description:

This is a multicenter study(approximately three) with over 450 subjects.Clinical data were collected by consulting the patient's electronic history. The data included demographic information, blood biochemical markers, clinical characteristics and electromyography. All participants provided their written informed consent to participate in this study.

Recruitment information / eligibility
Status Recruiting
Enrollment 450
Est. completion date January 31, 2025
Est. primary completion date December 1, 2022
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients fulfilled clinical, biological, and electrophysiology criteria for Guillain-barre syndrome. Exclusion Criteria: - nonidiopathic Guillain-barre syndrome and Miller Fisher syndrome

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang

Sponsors (1)
Lead Sponsor Collaborator
First Affiliated Hospital of Wenzhou Medical University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary the severity of Guillain-barre syndrome The Guillain-Barre syndrome disability score is a wide scale for the severity of Guillain-Barre syndrome (0, optimal health; 1, minor symptoms, able to run; 2, able to walk unaided 10 m, unable to run; 3, able to walk 10 m across an open space with help; 4 bedridden or wheelchair users; 5, require assisted ventilation; 6, dead)(deceased).The higher the score, the worse the prognosis. baseline, at 1 week, at 26 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04053452 - Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome N/A
Recruiting NCT02582853 - sCD163 as a Potential Biomarker in Guillain- Barré Syndrome N/A
Completed NCT00056810 - Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Phase 2
Completed NCT05104762 - IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients Phase 2/Phase 3
Recruiting NCT05630313 - Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
Recruiting NCT03801135 - Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation N/A
Active, not recruiting NCT01655394 - Change of Nerve Conduction Properties in IVIg Dependent Neuropathies N/A
Completed NCT04927598 - Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Not yet recruiting NCT04092140 - Neuromuscular Ultrasound in Correlation to Neurophysiological Findings
Not yet recruiting NCT04550611 - Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome N/A
Withdrawn NCT03268304 - Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments
Not yet recruiting NCT05701189 - Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome Phase 2
Withdrawn NCT02459808 - Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome N/A
Completed NCT04752566 - A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome Phase 3
Completed NCT05292690 - An Assistive Powered Wheelchair: Stage 2 Trial
Not yet recruiting NCT06300359 - Prognostic Indicators of Gullian-Barre Syndrome
Completed NCT00575653 - Safety Study of GBS Following Menactra Meningococcal Vaccination N/A
Completed NCT05491096 - Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome N/A
Not yet recruiting NCT05114941 - Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome N/A